Objective: To analyse drug consumption in the first years of rheumatoid arthritis (RA) in France, the Netherlands, and Norway, in a longitudinal study between 1991 and 1993.Patients and Methods: The EURIDISS cohort followed up over three years included 695 RA subjects with less than 5 years disease duration. Clinical and biological parameters, drug consumption according to ATC classification, and use of local treatment were recorded.Results: In the Netherlands consumption of second-line treatment occurred early on, and remained constant over time. Tn France, it was consumed by half of the subjects and decreased during follow-up (p <0.001). In Norway, 50% of the subjects were on second-line treatment at the outset. NSAIDs rather than cort...
Objectives The emergence of targeted therapy is changing rheumatoid arthritis (RA) management, but r...
Objectives. To describe the use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment ...
Abstract Background Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD...
Objective: To analyse drug consumption in the first years of rheumatoid arthritis (RA) in France, th...
Objective: To analyse drug consumption in the first years of rheumatoid arthritis (RA) in France, th...
Clinical and biological parameters, drug consumption according to ATC classification, and use of loc...
Objective: To study prescription patterns of biological treatment in rheumatoid arthritis ( RA) pati...
Objectives: to describe current disease-modifying antirheumatic drugs (DMARDs) prescription in rheum...
Objective. To study prescription patterns of biological treatment in rheumatoid arthritis (RA) patie...
Purpose: To explore the use of the biological tumour necrosis factor alpha (TNFalpha) inhibitors use...
OBJECTIVE: In Switzerland, the prescription of biologic antirheumatic agents in rheumatoid arthritis...
Objectives: To evaluate nationwide incidence, sociodemographic associations and treatment penetratio...
The aim of this study was to compare the socioeconomic consequences of early and late rheumatoid art...
Background: In this retrospective cohort study, we evaluated the drug therapies used for early rheum...
This retrospective medical chart review aimed to provide a current, real-world overview of biologic ...
Objectives The emergence of targeted therapy is changing rheumatoid arthritis (RA) management, but r...
Objectives. To describe the use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment ...
Abstract Background Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD...
Objective: To analyse drug consumption in the first years of rheumatoid arthritis (RA) in France, th...
Objective: To analyse drug consumption in the first years of rheumatoid arthritis (RA) in France, th...
Clinical and biological parameters, drug consumption according to ATC classification, and use of loc...
Objective: To study prescription patterns of biological treatment in rheumatoid arthritis ( RA) pati...
Objectives: to describe current disease-modifying antirheumatic drugs (DMARDs) prescription in rheum...
Objective. To study prescription patterns of biological treatment in rheumatoid arthritis (RA) patie...
Purpose: To explore the use of the biological tumour necrosis factor alpha (TNFalpha) inhibitors use...
OBJECTIVE: In Switzerland, the prescription of biologic antirheumatic agents in rheumatoid arthritis...
Objectives: To evaluate nationwide incidence, sociodemographic associations and treatment penetratio...
The aim of this study was to compare the socioeconomic consequences of early and late rheumatoid art...
Background: In this retrospective cohort study, we evaluated the drug therapies used for early rheum...
This retrospective medical chart review aimed to provide a current, real-world overview of biologic ...
Objectives The emergence of targeted therapy is changing rheumatoid arthritis (RA) management, but r...
Objectives. To describe the use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment ...
Abstract Background Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD...